Ex-Valeant and specialty pharmacy execs charged in kickback scheme

By Erica Teichert  |  November 17, 2016

Federal prosecutors on Thursday charged a former Valeant Pharmaceuticals executive and the ex-CEO of a specialty pharmacy for masterminding a multimillion fraud and kickback scheme that promoted the pharmacy's business for their own personal gain.

Mylan boosts EpiPen patient programs, doesn't budge on price

By Associated Press  |  August 25, 2016

Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has soared over the past decade. But the drugmaker didn't budge on its price hikes Thursday.

Valeant, attempting to normalize operations, names new CFO

By Associated Press  |  August 22, 2016

Valeant Pharmaceuticals replaced Robert Rosiello as chief financial officer as the embattled company attempts to normalize operations amid a host of ongoing investigations and class action lawsuits.

Q&A: 'Drug prices are the wrong target,' says PhRMA chief

Q&A: 'Drug prices are the wrong target,' says PhRMA chief

By Modern Healthcare  |  April 30, 2016

A nimble inside-the-Beltway operative, Stephen Ubl took the reins of the Pharmaceutical Research and Manufacturers of America just as outrage over high drug prices was hitting its peak. In an interview with Modern Healthcare Editor Merrill Goozner, Ubl shares his views on the drug-price debate.

Valeant files overdue financial report, ending debt default

By Associated Press  |  April 29, 2016

Valeant Pharmaceuticals resolved its default on some of its $30 billion in debt by finally filing its long-overdue U.S. financial report for 2015 on Friday. The badly tarnished Canadian drugmaker also announced a slate of mostly new nominees for elections to its board in June.

Valeant CEO will cite 'mistakes' in price-hiking strategy

By Associated Press  |  April 27, 2016

The outgoing CEO of embattled drugmaker Valeant Pharmaceuticals will tell lawmakers Wednesday that he was "too aggressive" and made mistakes in significantly hiking prices for several critical medicines, according to testimony provided to the Associated Press.

Lawmakers blast Valeant for price-gouging tactics

By Associated Press  |  April 27, 2016

Lawmakers accused drugmaker Valeant Pharmaceuticals of gouging patients to reward Wall Street investors at a hearing Wednesday focused on the embattled drugmaker's pricing tactics.

Middle-aged whites account for one-third of U.S. suicides

By Modern Healthcare  |  April 23, 2016

Middle-aged white people now account for one-third of all suicides in the U.S., according to the Centers for Disease Control and Prevention. Suicide is the nation’s 10th leading cause of death, and the overall rate rose 24% in 15 years.

Right-to-die group comes up with new, cheaper medication

By Associated Press  |  April 04, 2016

Right-to-die advocates in Washington state have created a cheaper alternative mixture of medications to help terminally ill patients legally end their lives after a drug company abruptly hiked the price of a drug commonly used for the purpose.


Subscribe and SAVE 50%

View our best offer
Subscribe to Print